Intraday Price Movement and Market Context
On 21 Nov 2025, Kopran’s stock recorded an intraday low of Rs.129, representing a decline of 3.73% during the trading session. The day’s overall change showed a fall of 2.95%, underperforming its sector by 2.68%. This movement places the stock below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained downward momentum.
In contrast, the broader market index, Sensex, opened lower by 285.28 points and was trading at 85,344.16, down 0.34%. Notably, Sensex remains close to its 52-week high of 85,801.70, just 0.54% away, and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish trend in the market overall.
Long-Term Price Performance
Over the past year, Kopran’s stock has recorded a return of -34.86%, a stark contrast to the Sensex’s positive 10.60% return during the same period. The stock’s 52-week high was Rs.236.10, highlighting the extent of the decline from its peak. This underperformance extends beyond the last year, with Kopran also lagging behind the BSE500 index over the last three years, one year, and three months.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
Financial Results and Profitability Trends
Kopran’s recent financial disclosures reveal a continuing pattern of negative results. The company reported a fall in net sales by 22.2% in the September 2025 quarter, marking the fifth consecutive quarter of negative results. The profit after tax (PAT) for the quarter stood at Rs. -9.92 crores, reflecting a decline of 234.4% compared to the previous period.
Operating profit has shown a negative compound annual growth rate of 11.79% over the last five years, indicating subdued long-term growth. The company’s return on capital employed (ROCE) for the half-year period is at a low 5.38%, while the operating profit to interest ratio for the quarter is at -2.53 times, suggesting challenges in covering interest expenses from operating earnings.
Valuation and Debt Profile
Despite the financial setbacks, Kopran maintains a relatively low average debt-to-equity ratio of 0.23 times, which is modest compared to many peers in the pharmaceuticals sector. The company’s ROCE of 4.7 and an enterprise value to capital employed ratio of 1.2 indicate that the stock is trading at a valuation discount relative to its historical peer averages.
However, the stock’s profits have contracted by 66.7% over the past year, which aligns with the downward pressure on its share price. The limited presence of domestic mutual funds, holding only 0.01% of the company, may reflect a cautious stance given the company’s recent financial trajectory.
Is Kopran your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Sector and Peer Comparison
Kopran operates within the Pharmaceuticals & Biotechnology sector, which has seen varied performance across companies. While the broader sector has maintained relative stability, Kopran’s stock has not kept pace with sector averages or the broader market indices. The stock’s current trading levels are significantly below its 52-week high and all major moving averages, underscoring the divergence from sector trends.
The company’s subdued sales and profitability metrics contrast with some peers that have managed to sustain growth or stabilise earnings, contributing to Kopran’s relative underperformance in the market.
Summary of Key Metrics
To summarise, Kopran’s stock price at Rs.129 represents a 52-week low, with a year-to-date return of -34.86%. The company’s net sales have contracted by 22.2% in the latest quarter, and profits have declined sharply by 234.4% in the same period. Operating profit trends over five years show a negative annual rate of 11.79%, while the ROCE remains low at 5.38%. The stock trades below all major moving averages and has underperformed both its sector and the Sensex index.
These factors collectively illustrate the challenges faced by Kopran in maintaining market valuation and financial performance amid a competitive and evolving pharmaceuticals landscape.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
